Dr Pritinder K. Thind, MD is an expert in nuclear medicine imaging and treatment. She administers radioactive iodine (I-131) therapy for patients with thyroid cancer, such as papillary thyroid carcinoma, follicular thyroid carcinoma, or Hurthle cell thyroid carcinoma.
Based on the chosen protocol, either Levothyroxine withdraw or Thyrogen stimulation is performed prior to administration of I-131 therapy. Determination of the protocol is chosen by your endocrinologist, based on your disease severity and also based on your insurance. Both, levothyroxine withdraw or Thyrogen stimulation, are equally efficient, but there are some minor differences are exist.
Patient who were undergoing I-131 therapy should be isolated. The extent and length of isolation is determined by a dose and will be discussed with you by Dr. Thind prior to therapy.
There are other resources available to patients with thyroid cancer who undergoing therapy with I-131 such as Dosimetry. Dosimetry is a calculation of a maximal I-131 doses need for your specific therapy.